Key Record Dates
| ClinicalTrials.gov Identifier: | NCT02684292 |
|---|---|
| Brief Title: | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) |
| First Submitted : | February 12, 2016 |
| First Submitted that Met QC Criteria : | February 12, 2016 |
| First Posted : | February 17, 2016 (Estimate) |
| Last Update Submitted that Met QC Criteria : | August 18, 2022 |
| Last Update Posted : | August 19, 2022 |